9 nominees · 3 ballot items.
Election of nine directors; Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026; Non-binding advisory approval of named executive officer compensation (Say-on-Pay).
Election of nine director nominees named in the proxy statement to serve until the 2027 annual meeting.
Ratify the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year 2026.
Non-binding, advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.
This proposal requests an advisory, non-binding endorsement of the Company’s executive compensation policies and payouts for the named executive officers for 2025 as disclosed in the proxy statement. Management seeks shareholder approval to demonstrate alignment with shareholders and to continue its pay-for-performance framework which emphasizes variable compensation, PSUs, RSUs and annual bonuses tied to revenue and adjusted EBITDA metrics; the Compensation Committee used peer benchmarking, engagement with large stockholders and retained an independent compensation consultant in setting targets. The advisory vote does not bind the Board or alter fiduciary duties but the Board and Compensation Committee will consider the vote outcome in future compensation decisions; historically, the 2025 say-on-pay received ~99% support. The Board recommends a vote FOR, arguing that their compensation program balances short- and long-term incentives, includes robust governance features (clawback policy, stock ownership guidelines, no hedging), and uses conservative severance structures. The potential shareholder argument against may center on pay quantum, or specific large grants (e.g., strategic achievement award to CEO), but management contends those were justified by performance, retention needs and market alignment. The vote serves as an important signal to the Compensation Committee and the Board on investor sentiment regarding executive pay and will be considered in subsequent compensation determinations.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JPMORGAN CHASE CO | 29.53% | 52,021,211 | $108M |
| 2 | Neuberger Berman Group LLC | 9.86% | 17,361,988 | $33M |
| 3 | DIMENSIONAL FUND ADVISORS LP | 3.50% | 6,157,404 | $13M |
| 4 | ROYCE ASSOCIATES LP | 2.77% | 4,879,741 | $10M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.39% | 4,216,459 | $9M |
| 6 | BlackRock, Inc. | 2.05% | 3,610,514 | $8M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.89% | 3,335,665 | $7M |
| 8 | BlackRock, Inc. | 1.36% | 2,392,691 | $5M |
| 9 | Connor, Clark Lunn Investment Management Ltd. | 1.19% | 2,089,722 | $4M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.18% | 2,082,443 | $4M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.